Analysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) PT at $48.20

Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) have earned an average rating of “Buy” from the seven research firms that are covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $48.20.

A number of analysts recently issued reports on the stock. Ascendiant Capital Markets dropped their target price on shares of Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. Chardan Capital reissued a “buy” rating and set a $53.00 target price on shares of Outlook Therapeutics in a research report on Friday, August 16th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Outlook Therapeutics in a research report on Thursday, August 15th.

Outlook Therapeutics Stock Down 8.3 %

NASDAQ OTLK opened at $5.93 on Tuesday. Outlook Therapeutics has a 12 month low of $4.09 and a 12 month high of $18.00. The company has a 50-day moving average of $7.63 and a 200-day moving average of $7.88.

Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.23. On average, sell-side analysts forecast that Outlook Therapeutics will post -3.65 EPS for the current year.

Hedge Funds Weigh In On Outlook Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of OTLK. Rosalind Advisors Inc. purchased a new position in Outlook Therapeutics in the 1st quarter worth approximately $3,723,000. Great Point Partners LLC boosted its stake in shares of Outlook Therapeutics by 15.0% during the 2nd quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock valued at $12,557,000 after buying an additional 221,510 shares during the last quarter. LVW Advisors LLC purchased a new position in shares of Outlook Therapeutics during the 2nd quarter valued at approximately $352,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Outlook Therapeutics during the 2nd quarter valued at approximately $303,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Outlook Therapeutics during the 2nd quarter valued at approximately $232,000. Hedge funds and other institutional investors own 11.20% of the company’s stock.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.